search
Back to results

Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease (AEROPROTECT)

Primary Purpose

Parkinson's Disease

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
High Intensity Aerobic program
Conventional Physical Therapy
Medium Intensity Aerobic program
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson's Disease focused on measuring Parkinson's disease, Aerobic Exercises, High Intensity Training, Neuroprotection

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of PD according to the UKPDSBB criteria
  • Previous MRI available, to further help distinguish idiopathic PD from atypical parkinsonism Hoehn & Yahr Stage 1-3 in OFF state
  • Age > 18
  • Signed informed consent to participate in study

Exclusion Criteria:

  • Patients lacking motivation or ability to participate in training sessions for 9 months, in the investigator's opinion
  • Contra-indications to high-intensity aerobic training in the cardiologist's opinion
  • Contra-indications to perchlorate de potassium or to the use of 123I-FP-CIT
  • Concurrent severe co-morbidities
  • Cognitive deficit limiting participation to the program in the investigator's opinion
  • Montreal Cognitive Assessment test (MoCA)<23
  • Uninsured patient
  • Participation in another ongoing interventional clinical trial (drug therapy, surgical treatment, another rehabilitation treatment, medical device)
  • Pregnancy or current lactation, or no efficacious contraception during the 9 months of intervention.

Sites / Locations

  • Henri Mondor Hospital
  • Sébastopol hospital
  • Rangueil hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Sham Comparator

Experimental

Arm Label

Conventional Physical Therapy

Medium Intensity Aerobic exercise (50% VO2 max)

High Intensity Aerobic exercise

Arm Description

Three sessions a week of hospital-based conventional physical therapy, all in presence and with the guidance of a registered physical therapist, for nine months

Three sessions a week of hospital-based Medium Intensity Aerobic exercise (50% VO2 max); on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months

Three sessions a week of hospital-based High Intensity Aerobic exercise (70% VO2 max) on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months

Outcomes

Primary Outcome Measures

Change in MDS-UPDRS III Score (Movement Disorders Society - Unified Parkinson's Disease Rating Scale) in the " OFF " state between Day 1 and Month 9.
The MDS-UPDRS III Score is a subjective assessment of motor symptoms based on the addition of ordinal 1-4 scores.

Secondary Outcome Measures

Two-minute walking test at maximal speed
Modified 20-meter up-and-go test (AT20)
Global Mobility Task (GMT)
time required to stand up off the floor
Upper limb performance in activities of daily living (Mount Sinai Parkinsonism Impairment Rating Scale, MSPIR)
three unimanual tasks on each side and six bimanual everyday living tasks all times
Maximal aerobic capacity (VO2 max)
Montreal Cognitive Assessment test (MoCA)
Digit span task (forward and backward)
Trail Making Test

Full Information

First Posted
August 2, 2019
Last Updated
August 2, 2019
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT04046276
Brief Title
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
Acronym
AEROPROTECT
Official Title
Neuroprotective, Motor and Cognitive Impact of a Long-standing Aerobic Training Program in Parkinson's Disease. A Multicenter Comparison of the Effects of Two Aerobic Programs of Graded Intensities and a Conventional Physical Therapy Program Prolonged for 9 Months on Nigrostriatal, Motor and Cognitive Functions.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Unknown status
Study Start Date
September 2019 (Anticipated)
Primary Completion Date
June 2021 (Anticipated)
Study Completion Date
November 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In phenotypic animal models of Parkinson's Disease (PD), chronic physical exercise has produced nigrostriatal neuroprotection and symptom improvement, provided training was of high-intensity and prolonged duration (>3 months in rodent models). Conventional physical therapy in Parkinson's disease (PD) has traditionally avoided fatigue and high intensity workouts. Yet, in PD controlled studies have shown that: (i) an acute aerobic stress produces endogenous dopamine immediately after the exercise and (ii) short term (a few weeks) high intensity aerobic training enhances D2 striatal receptor density and cortical excitability and clinically improves walking, upper limb and executive functions; (iii) long-term (six months) high intensity aerobic treadmill training is associated with less deterioration of subjective UPDRS III score compared to a waiting list. Long-term high intensity aerobic training has not been compared to low or medium intensity training in PD patients for its objective motor, cognitive and putative neuroprotective effects.
Detailed Description
A short description, 5000 characters Intro: In phenotypic animal models of Parkinson's Disease (PD), chronic physical exercise has produced nigrostriatal neuroprotection and symptom improvement, provided training was of high-intensity and prolonged duration (>3 months in rodent models). Conventional physical therapy in Parkinson's disease (PD) has traditionally avoided fatigue and high intensity workouts. Yet, in PD controlled studies have shown that: (i) an acute aerobic stress produces endogenous dopamine immediately after the exercise and (ii) short term (a few weeks) high intensity aerobic training enhances D2 striatal receptor density and cortical excitability and clinically improves walking, upper limb and executive functions; (iii) long-term (six months) high intensity aerobic treadmill training is associated with less deterioration of subjective UPDRS III score compared to a waiting list. Long-term high intensity aerobic training has not been compared to low or medium intensity training in PD patients for its objective motor, cognitive and putative neuroprotective effects. Hypothesis/Objective Hypothesis High-intensity aerobic exercises practiced over 9 months will produce greater symptomatic motor and cognitive benefits and neuroprotective effects in PD patients, than low or medium intensity training. Primary Objective To compare the motor effects of a 9-month conventional physical therapy program (light aerobic exercises), an aerobic program of medium intensity on stationary bicycle (50% maximal oxygen uptake, VO2 max), and an aerobic program of high intensity (70% VO2 max) in Parkinson's disease. Secondary Objectives To evaluate aerobic capacities before and after the program. To evaluate cognitive functions, depression, quality of life before and after each program as well as 3 months following program termination and motor function 3 months following program termination. To explore potential neuroprotective effects of a 9-month aerobic program through specialized brain imaging (123I-Ioflupane SPECT) and a potential aerobic intensity-effect of such neuroprotection. Primary outcome measure Change in MDS-UPDRS III Score (Movement Disorders Society - Unified Parkinson's Disease Rating Scale) in the " OFF " state between Day 1 and Month 9. Secondary outcome measures OFF-state at Day 1, Month 9, Month 12 Two-minute walking test from D1 to M9 Modified 20-meter up-and-go test (AT20) 2-minute walk test (from M1 to M12) Global Mobility Task (GMT) scale (standing up off the floor) Upper limb performance in activities of daily living (Mount Sinai Parkinsonism Impairment Rating Scale, MSPIR) Static posturography Maximal aerobic capacity (VO2 max) Montreal Cognitive Assessment test (MoCA) Digit span task (forward and backward) Trail Making Test ON-state at D1, M9, M12 MDS-UPDRS III Score; Mean number of steps performed over the past three weeks (pedometry); Monthly incidence of falls in the past 3 months (questionnaire) Daily consumption of dopaminergic medications Quality of life (EQ-5D) Depression (GDS15) Dopaminergic striatal function by SPECT [123I] beta-CIT striatal uptake at D1, M12. Method Design Single-blind randomized study, 3 parallel groups (n= 7 or 8 per group and per center, over 3 centers): Group 1 " High Intensity Aerobic exercise ", HIA (70% VO2 max); Group 2 " Medium Intensity Aerobic exercise ", MIA (50% VO2 max); Group 3 " Conventional Physical Therapy ", CPT HIA and MIA groups are experimental groups and CPT group is the control group. Each group will attend 3 weekly 45-minute sessions at the hospital for 9 months. Number of subjects needed: 69 Inclusion criteria Patients with diagnosis of PD according to the UKPDSBB criteria to distinguish idiopathic PD from atypical parkinsonism such as multi-system atrophy, progressive supra-nuclear paralysis or vascular parkinsonism; Previous MRI available, to further help distinguish idiopathic PD from atypical parkinsonism; Hoehn & Yahr Stage 1-3 in OFF state; Age > 18; Signed informed consent to participate in study. Non-inclusion criteria Patients lacking motivation or ability to participate in training sessions for 9 months, in the investigator's opinion; contra-indications to high-intensity aerobic training in the cardiologist's opinion; contra-indications to perchlorate de potassium or to the use of 123I-FP-CIT; concurrent severe co-morbidities; cognitive deficit limiting participation to the program; Montreal Cognitive Assessment test (MoCA)<23; uninsured patient; participation in another ongoing interventional clinical trial (drug therapy, surgical treatment, another rehabilitation treatment, medical device); Pregnancy or current lactation, or no efficacious contraception during the 9 months of intervention. Recruitment period: 1 year; Study duration: 26 months (24 patients recruited in 2 centers and 21 patients in the other 2 centers) Participation duration for each patient: 14 months Number of participating centers: 3

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson's Disease
Keywords
Parkinson's disease, Aerobic Exercises, High Intensity Training, Neuroprotection

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Single-blind randomized study, three parallel groups (n= 7 or 8 per group and per center, over 3 centers): Group 1 "Conventional Physical Therapy", CPT Group 2 "Medium Intensity Aerobic program", MIA (50% VO2 max); Group 3 "High Intensity Aerobic program", HIA (70% VO2 max); HIA and MIA groups are experimental groups and CPT group is the control group. Each group will attend 3 weekly 45-minute sessions at the hospital for 9 months.
Masking
InvestigatorOutcomes Assessor
Masking Description
Study participants will be unaware of the hypothesis. All investigator assessors, clinical, cardiological, biomechanical or through SPECT [123I] beta-CIT striatal uptake measurements, will be unaware of the participant group
Allocation
Randomized
Enrollment
69 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Conventional Physical Therapy
Arm Type
Placebo Comparator
Arm Description
Three sessions a week of hospital-based conventional physical therapy, all in presence and with the guidance of a registered physical therapist, for nine months
Arm Title
Medium Intensity Aerobic exercise (50% VO2 max)
Arm Type
Sham Comparator
Arm Description
Three sessions a week of hospital-based Medium Intensity Aerobic exercise (50% VO2 max); on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
Arm Title
High Intensity Aerobic exercise
Arm Type
Experimental
Arm Description
Three sessions a week of hospital-based High Intensity Aerobic exercise (70% VO2 max) on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
Intervention Type
Behavioral
Intervention Name(s)
High Intensity Aerobic program
Intervention Description
Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
Intervention Type
Other
Intervention Name(s)
Conventional Physical Therapy
Intervention Description
Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
Intervention Type
Behavioral
Intervention Name(s)
Medium Intensity Aerobic program
Intervention Description
Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
Primary Outcome Measure Information:
Title
Change in MDS-UPDRS III Score (Movement Disorders Society - Unified Parkinson's Disease Rating Scale) in the " OFF " state between Day 1 and Month 9.
Description
The MDS-UPDRS III Score is a subjective assessment of motor symptoms based on the addition of ordinal 1-4 scores.
Time Frame
at day 1 and 9 Months
Secondary Outcome Measure Information:
Title
Two-minute walking test at maximal speed
Time Frame
at day 1, 9 Months and 12 Months
Title
Modified 20-meter up-and-go test (AT20)
Time Frame
at day 1, 9 Months and 12 Months
Title
Global Mobility Task (GMT)
Description
time required to stand up off the floor
Time Frame
at day 1, 9 Months and 12 Months
Title
Upper limb performance in activities of daily living (Mount Sinai Parkinsonism Impairment Rating Scale, MSPIR)
Description
three unimanual tasks on each side and six bimanual everyday living tasks all times
Time Frame
at day 1, 9 Months and 12 Months
Title
Maximal aerobic capacity (VO2 max)
Time Frame
at day 1, 9 Months and 12 Months
Title
Montreal Cognitive Assessment test (MoCA)
Time Frame
at day 1, 9 Months and 12 Months
Title
Digit span task (forward and backward)
Time Frame
at day 1, 9 Months and 12 Months
Title
Trail Making Test
Time Frame
at day 1, 9 Months and 12 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of PD according to the UKPDSBB criteria Previous MRI available, to further help distinguish idiopathic PD from atypical parkinsonism Hoehn & Yahr Stage 1-3 in OFF state Age > 18 Signed informed consent to participate in study Exclusion Criteria: Patients lacking motivation or ability to participate in training sessions for 9 months, in the investigator's opinion Contra-indications to high-intensity aerobic training in the cardiologist's opinion Contra-indications to perchlorate de potassium or to the use of 123I-FP-CIT Concurrent severe co-morbidities Cognitive deficit limiting participation to the program in the investigator's opinion Montreal Cognitive Assessment test (MoCA)<23 Uninsured patient Participation in another ongoing interventional clinical trial (drug therapy, surgical treatment, another rehabilitation treatment, medical device) Pregnancy or current lactation, or no efficacious contraception during the 9 months of intervention.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jean-Michel GRACIES, MD, PhD
Phone
+33 1 49 81 30 61
Email
jean-michel.gracies@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Nicolas BAYLE, MD
Phone
+33 1 49 81 30 61
Email
nicolas.bayle@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Michel GRACIES, MD, PhD
Organizational Affiliation
Assistance Publique Hôpitaux de Paris (AP-HP)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Henri Mondor Hospital
City
Créteil
ZIP/Postal Code
94010
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Michel GRACIES, MD, PhD
Phone
+33 1 49 81 30 61
Email
jean-michel.gracies@aphp.fr
First Name & Middle Initial & Last Name & Degree
Nicolas BAYLE, MD
Phone
+33 1 49 81 30 61
Email
nicolas.bayle@aphp.fr
Facility Name
Sébastopol hospital
City
Reims
ZIP/Postal Code
51100
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
François Constant BOYER, MD,PH
Phone
+33 3 26 78 85 97
Email
fboyer@chu-reims.fr
Facility Name
Rangueil hospital
City
Toulouse
ZIP/Postal Code
31059
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marc LABRUNEE, MD
Phone
+33 5 61 32 28 01
Email
labrunee.m@chu-toulouse.fr

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION

Learn more about this trial

Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease

We'll reach out to this number within 24 hrs